


Ajinomoto Co., Inc. Third quarter-FY2013 Market and other information

1. Breakdown by Business Segment

(Billion Yen, figures in parenthesis represent
YoY change)

Net Sales 742.3 Billion Yen

Operating Income 50.8 Billion Yen



2. Breakdown of Each Business Segment

Segment	Business	Main Brands/Products
Domestic Food Products	Seasonings and Processed foods	Home use: <i>AJI-NO-MOTO</i> , <i>HONDASHI</i> , <i>Cook Do</i> , <i>Knorr Cup Soup</i> , <i>Ajinomoto KK Consomme</i> , <i>Pure Select Mayonnaise</i> , various Gift sets Restaurant and industrial use: seasonings and processed foods for restaurant use, Seasonings for processed food manufacturers*(savory seasonings, enzyme <i>ACTIVA</i>), Delicatessens and Bakery products *Overseas sales are included in domestic food products segment.
	Frozen foods	<i>Gyoza</i> (Chinese dumpling), <i>Yawaraka Wakadori Kara-Age</i> (fried chicken), <i>Ebi shumai</i> (shrimp dumpling), <i>Yoshokutei Hamburg</i> (hamburg steak), <i>AMOY</i> (overseas sales)
	Beverages ("Calpis") *1	Products of Calpis Co., Ltd. such as <i>CALPIS</i> , <i>CALPIS Water</i> , <i>AMEAL S</i>
Overseas Food Products	Consumer foods (mainly home use)	<i>AJI-NO-MOTO</i> (outside Japan), <i>Ros Dee</i> (flavor seasoning/Thailand), <i>Masako</i> (flavor seasoning/Indonesia), <i>Aji-ngon</i> (flavor seasoning/Vietnam), <i>Sazon</i> (mixed seasoning/Brazil), <i>AMOY</i> (Chinese ethnic sauce), <i>YumYum</i> (instant noodles/Thailand), <i>Birdy</i> (coffee beverage/Thailand)
	Umami seasonings for processed food mfrs.	<i>AJI-NO-MOTO</i> and nucleotides for processed food manufacturers *Domestic sales are also included in overseas food products segment.
Bioscience Products & Fine Chemicals	Feed-use amino acids	Feed-use Lysine, feed-use Threonine, feed-use Tryptophan
	Amino acids	Amino acids for pharmaceuticals and foods: Arginine, Glutamine, Valine (ex. for infusion, for beverages) Amino acid-based sweeteners: Aspartame, overseas retail sweetener products, <i>PAL SWEET</i> Pharmaceutical Custom Manufacturing*2: anti-cancer drugs, auto immune disease, anti-AIDS drugs, active ingredients for generics, natural extracts, etc.
	Specialty chemicals	Personal care ingredients: <i>Amisoft</i> (surfactants) Cosmetics: <i>Jino</i> Electronic materials: <i>ABF</i> (insulation film for build-up printed wiring board)
Pharmaceuticals	Prescription drugs	Prescription drugs: Gastrointestinal diseases (<i>LIVACT</i> , <i>ELENTAL</i>), Metabolic diseases, etc. (<i>ATELEC</i> , <i>FASTIC</i> , <i>ACTONEL</i>), Clinical nutrition (<i>SOLITA-T</i> , <i>PNTWIN</i>)*3
Other Business	-	Wellness: Fundamental foods (<i>Glyna</i> , <i>Capsiate Natura</i>), Functional foods (<i>amino VITAL</i>), Medical foods (<i>MEDIF</i> , <i>IMPACT</i>) Other: Logistics, Edible oils & Coffee products*4, Service, others

*1 On October 1, 2012, Ajinomoto Co. closed the sale of Calpis shares to Asahi Group Holdings, LTD.

*2 Pharmaceutical custom manufacturing (formerly pharmaceutical fine chemicals): A business that provides pharmaceutical intermediate and bulk drug manufacturing and development services to pharmaceutical manufacturers. From this first quarter, the results of Ajinomoto Althea, Inc. are reflected in this business.

*3 On July 1, 2013, AJINOMOTO PHARMACEUTICALS CO., LTD. spins off infusion and dialysis products (*SOLITA-T*, *PNTWIN*, etc.) into AY PHARMACEUTICALS CO., LTD.

*4 For the Edible oils & Coffee products, the gross figures for sales and cost of goods sales were recorded in the accounts but from FY2013 this method was changed by netting off sales and cost of goods sold and recording the net figure in the accounts. And the segment was changed from Business Tie-Ups to Other Business.

3. Domestic Food Products

(1) Market share and position of main brands in the Japanese household market (Ajinomoto estimate)* (Billion Yen)

Category	Brands	FY2012			FY2013	
		Market	Ajinomoto's %(rank)**		Market (est.)	Ajinomoto's %(rank)**
			1H-FY2012	FY2012		1H-FY2013
Umami seasonings	AJI-NO-MOTO, Hi-Me	7.2	92%(1)	91%(1)	6.9	91%(1)
Japanese flavor seasonings	HON-DASHI	40.1	46%(1)	45%(1)	38.9	44%(1)
Consomme	Ajinomoto KK Consomme	12.8	68%(1)	67%(1)	13.1	67%(1)
Soup	Knorr	83.5	35%(1)	38%(1)	85.0	34%(1)
Mayonnaise and mayonnaise-type dressings	Pure Select	43.9	27%(2)	26%(2)	43.9	29%(2)
Menu seasonings	Cook Do, Cook Do Kyo-no Ohzara	57.8	25%(1)	25%(1)	59.0	29%(1)

* Consumer purchase basis

** Database of Ajinomoto's % (rank) is mainly individuals from households of two or more persons and single persons

(2) Ratio of sales for home use/restaurant and industrial use (Billion Yen)

		1H-FY2012	Apr.-Dec. FY2012	FY2012	1H-FY2013	Apr.-Dec. FY2013
Seasonings and Processed foods*1	Sales	104.8	167.7	217.4	101.3	164.2
	Home use*2	57%	58%	59%	54%	57%
Frozen foods	Restaurant and institutional use*3	43%	42%	41%	46%	43%
	Sales for Japanese market	52.4	79.9	104.4	53.4	80.7
Frozen foods	Home use	63%	63%	63%	62%	62%
	Restaurant and institutional use	37%	37%	37%	38%	38%

*1 Previous years' figures for Kellogg's products restated as net sales less cost of sales.

*2 Home use includes seasonings & processed foods for home use and gift set.

*3 Restaurant and industrial use includes seasonings & processed foods for restaurant use, seasonings for processed food manufacturers, delicatessens and bakery products.

4. Overseas Food Products

Estimated demand for MSG and nucleotides (Thousand MT)

	FY2011				FY2012			
	China	Other	Total	Ajinomoto's %	China	Other	Total	Ajinomoto's %
MSG	1,460	1,340	2,800 *1	approx.20%	1,550	1,380	2,930 *2	approx.20%
Nucleotides	-	-	31	approx.35%	-	-	34	approx.35%

*1 retail: a little under 60%, industrial use: a little over 40%

*2 retail: a little under 60%, industrial use: a little over 40%

5. Bioscience Products & Fine Chemicals

(1) Market price and estimated market size of feed-use amino acids

		FY2010	FY2011	Q3-FY2012	FY2012	1H-FY2013	Q3-FY2013	FY2013 (est.)**
Spread (US\$/ST)*		140	95	190	190	230	270	approx. 240
Market Price (US\$/kg, CIF main port basis)	Lysine	2.00	2.35	2.20	2.15	1.70	1.50	approx. 1.65
	Threonine	2.55	2.45	2.50	2.30	2.15	2.00	approx. 2.10
Market size (Thousand MT)	Tryptophan	23	15	32	17	15	14	approx. 15
	Lysine	1,580	1,700		1,950			approx. 2,150
Market size (Thousand MT)	Ajinomoto's%	approx. 20%	approx. 20%		approx. 20%			15-20%
	Threonine	245	270		330			approx. 380
	Ajinomoto's%	approx. 35%	approx. 30%		approx. 30%			approx. 30%
	Tryptophan	4.8	6.0		9.0			approx. 13.0
Market size (Thousand MT)	Ajinomoto's%	approx. 55%	approx. 40%		approx. 45%			approx. 30%

* The price difference between soybean meal and corn on the Chicago Board of Trade (CBOT)

** Spread and market prices do not correspond with assumptions in Ajinomoto's forecast of results.

(2) Estimated market size of amino acid-based sweetener, aspartame

	FY2011		FY2012		FY2013(est.)	
	Market	Ajinomoto's%	Market	Ajinomoto's%	Market	Ajinomoto's%
Aspartame (Thousand MT)	approx.24.5	30-35%	approx.24.5	approx.30%	approx.25.0	approx.30%

6. Pharmaceuticals

(1) Sales* of main products (AJINOMOTO PHARMACUETICALS CO., LTD. estimate)

(Billion Yen)

Field	Main Products	Launch Date	Indication or Formulation	Marketing Company	FY2012	Apr.-Dec. 2013	Y/Y %
Gastro-intestinal diseases	LIVACT	May 1996	Amino acid formula for treatment of liver cirrhosis	AJINOMOTO PHARMACUETICALS CO., LTD.	14.9	11.5	99%
	ELENTAL	Sept. 1981	Elemental diet	AJINOMOTO PHARMACUETICALS CO., LTD.	7.7	5.9	100%
	MARZUREN	July 2012	Antigastritis and anti-ulcer drugs	AJINOMOTO PHARMACUETICALS CO., LTD.	2.8	2.7	140%
	NIFLEC	June 1992	Oral cleaning solution for the intestine	AJINOMOTO PHARMACUETICALS CO., LTD.	2.3	1.7	99%
	HEPAN ED	Sept. 1991	Elemental diet for hepatic failure	AJINOMOTO PHARMACUETICALS CO., LTD.	0.9	0.7	91%
Metabolic diseases, etc.	MOVIPREP	June 2013	Bowel preparation prior to colonoscopy and colon surgery	AJINOMOTO PHARMACUETICALS CO., LTD.	-	0.5	-
	ATELEC	Dec. 1995	Long-acting calcium channel blocker	Mochida Pharmaceutical Co., Ltd.	15.1	11.3	96%
	ACTONEL	May 2002	Osteoporosis treatment	Eisai Co., Ltd.	11.7	7.7	86%
	FASTIC	Aug. 1999	Fast-acting postprandial antihypoglycemic agent	Mochida Pharmaceutical Co., Ltd.	2.4	1.4	73%

* NHI (National Health Insurance) reimbursement price basis. Effect of NHI drug price revision implemented: April 2012 approx. -6%

(2) Development Pipeline

January, 2014

	Name	Development Status	Indication	Note
Gastrointestinal diseases	AJG511	Phase II	Ulcerative colitis	In-license (Dr. Falk Pharma)
	AJM300	Phase II	Ulcerative colitis	
Metabolic diseases	AJH801	NDA	Hypertension	
	<i>FASTIC</i>	Phase III	Type 2 Diabetes Mellitus	Combination therapy with DPP-4 inhibitor

(3) Newly Launched Products after January, 2013

January, 2014

Field	Name	Launch	Indication or Classification	Note
Gastrointestinal diseases	<i>MOVIPREP</i>	June, 2013	Bowel preparation prior to colonoscopy and colon surgery	
	<i>LIVACT</i>	July, 2013	Amino acid formula for treatment of liver cirrhosis	Additional formulation / Jellies for oral administration
Metabolic diseases	<i>ACTONEL</i>	February, 2013	Osteoporosis	Additional formulation / Monthly administration
	<i>ATELEC</i>	December, 2013	Hypertension	Additional formulation / 20mg Tablet

Note: This includes forward-looking statements based on a number of assumptions.

Actual results may differ substantially depending on a number of factors including but not limited to economic trends and exchange rates.

Amounts presented in this material are rounded off.